‘Vaccine tailor-made” for cancer book first success
Oncologists in Germany and the United States have for the first time, small groups of cancer patients treated with a “personalized’ vaccine.
That writes the Volkskrant on the basis of German and American research. The vaccine teaches the immune system the cancer to recognize. Although the vaccine is not when everyone is working, call the researchers the results are very promising.
The tests were a total of nineteen patients with advanced melanoma, a form of skin cancer, first surgery and then treated with a molecuulcocktail. This studied to the researchers, the tumor in detail, and then they have dozens of molecular characteristics of the tumors nabouwden in loose eiwitslierten.
That injected one then, as a signal to the immune system: “these pieces of the molecule are not, attack them if you put them somewhere”. Earlier, scientists from the Leiden University Centre for research into the same treatment method in mice.
The method is now with promising results, applied to people, write the teams of professor of experimental oncology, Ugur Sahin and Catherine Wu of the Dana-Farber Cancer Institute in Boston apart from each other in Nature. In the US remained the cancer in four of six patients a few years away; in the other two patients disappeared metastases of the scans after the practitioners the immune system extra opvoerden.
In Germany, where one works with a different vaccine, the disease way for eight of the thirteen patients. Two died, another patient disappeared, the disease is still. The vaccines to measure, in months time, molecule for molecule compound, for the ordinary behandelpraktijk still not on the cards, says Sahin, leader of the German experiment, if prompted. “The costs are still enormous, but can the next few years are drastically reduced if the process is automated.”
Professor of onco-immunologi at the Antoni van Leeuwenhoek hospital, Ton Schumacher will find the results a “substantial step forward” so he says to the newspaper. But beware, he warns. “it was to cure patients whose cancer surgery was removed. Therefore, this is not proof that the clinical effects can be substantial. We now have larger studies are needed. Because the evidence that this approach has an effect, are indeed strong.”
In the long term treatment should go for more cancers, say the researchers.